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Abstract
The Surviving Sepsis Campaign is a global effort to improve the care of patients with severe sepsis and septic shock.
The first Surviving Sepsis Campaign Guidelines were published in 2004 with an updated version published in 2008.
These guidelines have been endorsed by many professional organizations throughout the world and come regarded
as the standard of care for the management of patients with severe sepsis. Unfortunately, most of the
recommendations of these guidelines are not evidence-based. Furthermore, the major components of the 6-hour
bundle are based on a single-center study whose validity has been recently under increasing scrutiny. This paper
reviews the validity of the Surviving Sepsis Campaign 6-hour bundle and provides a more evidence-based approach
to the initial resuscitation of patients with severe sepsis.
Sepsis is among the most common reasons for admission
to intensive care units (ICUs) throughout the world. Dur-
ing the past two decades, the incidence of sepsis in the
United States has tripled and is now the tenth leading
cause of death. In the United States alone, approximately
750,000 cases of sepsis occur each year, at least 225,000
of which are fatal [1,2]. Septic patients are generally hos-
pitalized for extended periods, rarely leaving the ICU
before 2-3 weeks. Despite the use of antimicrobial agents
and advanced life-support, the case fatality rate for
patients with sepsis has remained between 20% and 30%
during the past 2 decades [1,2].
The Surviving Sepsis Campaign (SSC) is a global effort
to improve the care of patients with severe sepsis and sep-
tic shock. The campaign was launched by the Society of
Critical Care Medicine,t h eEuropean Society of Intensive
Care Medicine and the International Sepsis Forum in
2002. The first Surviving Sepsis Campaign Guidelines
were published in Critical Care Medicine in 2004 and
included 52 recommendations [3]. Ely Lily and Company
and Edwards Life Sciences sponsored the guideline pro-
cess, raising concerns about the integrity of the guidelines
[4]. Furthermore, it appeared that the guideline implemen-
tation process was part of the marketing strategy for the
Eli Lilly Company. The Surviving Sepsis Campaign Guide-
lines were updated in 2008, and although free of corporate
sponsorship and somewhat broader in scope (85
recommendations), the core recommendation’s remained
largely unchanged [5].
These core recommendations were principally based on
the results of a small, single-center study by Rivers et al.
(Early Goal-Directed Therapy [EGDT]) whose validity
has been recently under increasing scrutiny [6,7]. It is
important to note that the majority of recommendations
in both sets of guidelines were based on the lowest level
of scientific evidence (Grade E - uncontrolled studies,
case series and expert opinion). Barochia and colleagues
performed a systemic review of the association between
the component therapies of the Surviving Sepsis Cam-
paign 6-hour resuscitation bundle and outcome [8].
These authors concluded that the “current sepsis bundles
may force physicians to provide unproven or even harmful
care. As administered and studied to date, only antibio-
tics meet the stated criteria of proof for bundle inclusion.”
Evidence-based medicine is defined as “the conscien-
tious, explicit, and judicious use of the best current scienti-
fic evidence in making decisions about the care of
individual patients” [9]. The practice of evidence-based
medicine means integrating clinical acumen with patients’
unique clinical features and the best available external evi-
dence from systematic research. Clinical practice guide-
lines embrace evidence-based medicine by rigorously
distilling the highest level of evidence from the literature
in an effort to help physicians to provide the best possible
care to their patients. The principle construct of the guide-
line development process is that they should be evidence-
based and not opinion-based, be fully transparent, and
that the developers and sponsoring organization(s) should
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clear that the Surviving Sepsis Campaign Guidelines fail to
meet these requirements for guideline validity. Regrettably,
these guidelines have been endorsed by such organization
as the “Institute of Healthcare Improvement” and the
“Joint Commission” and have become regarded as the
standard of care in the United States and many European
counties. The Australian and New Zealand Intensive Care
Society (ANZICS) have, however, questioned the validity
of these guidelines. Due to concern that the guideline
“package” would inappropriately be adopted by quality
improvement programs and organizations, ANZICS
have declined to endorse the Surviving Sepsis Campaign
Guidelines [10].
It has become increasingly apparent that in many
patients there is a long delay in both the recognition of
sepsis and the initiation of appropriate therapy. This has
been demonstrated to translate into an increased inci-
dence of progressive organ failure and a higher mortality.
Kumar and colleagues investigated the relationship
between the duration of hypotension before antimicrobial
administration in 2,600 patients with sepsis-induced hypo-
tension [11]. They reported that the risk of dying increased
progressively with time to receipt of the first dose of anti-
biotic. The Surviving Sepsis Campaign and EGDT have
succeeded in putting the “spotlight” on sepsis and have
popularized the concept that the early identification and
treatment of sepsis is essential to improve the outcome of
this potentially fatal disease. The early identification of
sepsis, the early administration of appropriate antibiotics,
and early hemodynamic resuscitation remain the corner-
stone of the management of patients with sepsis. However,
as demonstrated by Barochia and colleagues, the major
components of the Surviving Sepsis Campaign 6-hour
resuscitation bundle are not evidence-based and should be
abandoned [8].
The hemodynamic alterations with sepsis are exceed-
ingly complex and include volume depletion, depressed
myocardial function, and altered microvascular flow.
These changes are dynamic; it has been reported that
patients with preserved ventricular function may progress
to develop severely depressed contractility [12]. In addi-
tion, with progressive volume loading patients may
develop severe tissue edema, which compromises tissue
oxygenation. This paradigm dictates that that the hemody-
namic profile of each patient be dynamically monitored
and that therapeutic interventions may need be modified
based on these changes [13]. Furthermore, it is evident
that the complexity of these changes defies a simple treat-
ment algorithm. The major elements of the “6-hour resus-
citation bundle” of the Surviving Sepsis Campaign
Guidelines include fluid resuscitation to achieve a central
venous pressure (CVP) of >8 cmH2O (or 12 cmH2Ow h e n
on a ventilator) and a central venous oxygen saturation
(ScvO2) > 70% with the use of blood and inotropic agents.
There is increasing recognition that the major elements of
this bundle are not supported by scientific evidence
[8,10,14,15]. Remarkably, these recommendations are
based on a small (n = 263), nonblinded, single-center
study (the River’s EGDT study) [6], in which the lead
author had significant undisclosed conflicts of interest and
where the validly of the data has been questioned [7].
Furthermore, it is noteworthy that the reported hospital
mortality of the standard therapy group in the River’s
EGDT study was 46%; this compares to 17% in a recent
randomized, controlled study that evaluated the outcomes
of the 6-hour resuscitation bundle [16].
During the first hours of severe sepsis, venodilatation,
transudation of fluid from the vascular space into the tis-
sues, reduced oral intake, and increased insensible loss
combine to produce hypovolemia [17]. Ventricular dys-
function and arteriolar dilation volume depletion contri-
bute to impaired global perfusion and organ function.
Treating hypovolemia is the most important component
of the early management of severe sepsis. However, once
the patient has received an adequate fluid challenge,
further fluid challenges may not increase cardiac output
and global perfusion [13]. Additional fluid may increase
interstitial edema and further comprise the microvascular
dysfunction that characterizes severe sepsis. The current
paradigm of fluid management in patients with sepsis is
one of adequate initial fluid resuscitation followed by con-
servative late-fluid management. Conservative late-fluid
management is defined as even-to-negative fluid balance
measured on at least 2 consecutive days during the first 7
days after septic shock onset. In a retrospective cohort
study, Murphy and colleagues demonstrated that an
approach that combines both adequate initial fluid resusci-
tation followed by conservative late-fluid management was
associated with improved survival [18]. A retrospective
analysis of the Vasopressin in Septic Shock Trial (VASST)
demonstrated that those patients in the quartile with the
largest positive fluid balance at both 12 hours and 72
hours had the highest mortality [19]. Additional studies
have demonstrated that those patients who have the lar-
gest cumulative fluid balance have an increased mortality
[20-22].
The optimal time to initiate vasopressor agents has not
been rigorously studied. Many patients with severe sepsis
will respond to a 2-L fluid challenge and require little
additional hemodynamic support. If despite adequate
intravascular filling a mean arterial pressure in excess of
65 mmHg cannot be achieved, then vasoconstrictors must
be used [23]. The early use of vasoconstrictors is recom-
mended, because it reduces the incidence of organ failure
and may prevent excessive volume overload (conservative
late fluid management) [23]. Therefore, we recommend
that a vasopressor agent (norepinephrine) be started once
Marik Annals of Intensive Care 2011, 1:17
http://www.annalsofintensivecare.com/content/1/1/17
Page 2 of 6the patient has received 2 L of crystalloid (NS) [17,24,25].
In cases of life-threatening hypotension (i.e., diastolic
blood pressure < 40 mmHg), treatment with vasopressors
must be started immediately and concurrently with fluid
resuscitation [23]. Norepinephrine (starting at 0.01 μg/kg/
min) should be titrated upwards while fluid resuscitation
continues. Figure 1 provides an initial approach to the
resuscitation of patients with septic shock; however, it is
important to emphasize that these patients require close
hemodynamic monitoring with dynamic changes as
the hemodynamic course evolves. Ongoing fluid and vaso-
pressor resuscitation should be guided by mean arterial
pressure, pulse pressure variation, passive leg-raising man-
euvers, urine output, oxygenation as well as cardiac output
(determined noninvasively), and extravascular lung water
measurement [13,26,27]. Bedside echocardiography is cri-
tical to determine left ventricular size and function. The
central venous pressure (CVP) does not reflect intravascu-
lar volume nor does it predict fluid responsiveness and
has no place in the resuscitation of patients with sepsis
[13,28,29]. Interestingly, in the VASST study those
patients who met the Surviving Sepsis Campaign CVP tar-
get had the highest mortality [19]. Although there is scant
data to suggest that one vasopressor results in better
outcomes than another (norepinephrine, epinephrine,
vasopressin) [24,30-32], we favor norepinephrine as the
first-line agent followed by dobutamine or epinephrine in
patients with poor left ventricular (LV) function and vaso-
p r e s s i n( f i x e dd o s eo f0 . 0 3u / m i n )i np a t i e n t sw i t h
“preserved” LV function and a low systemic vascular resis-
tance (SVR; Figure 1). In patients with sepsis, norepi-
nephrine increases blood pressure, as well as cardiac
output, renal, splanchnic, cerebral blood flow, and micro-
vascular blood flow while minimally increasing heart rate
[33,34]. Norepinephrine seems to be the ideal first-line
agent for the management of septic shock; additional
agents should be considered in patients who remain hypo-
tensive or display evidence of inadequate tissue or organ
perfusion despite doses of norepinephrine up to 0.2 μg/kg/
min. The second/third-line agents should be chosen based
on the patient’s hemodynamic profile as determined by
ECHO and noninvasive assessment of cardiac output.
Dopamine has a number of theoretical disadvantages in
patients with sepsis. It tends to increase heart rate,
increases myocardial oxygen demand, and is associated
with splanchnic mucosal ischemia. In addition, dopamine
inhibits T and B lymphocytes and decreases secretion of
prolactin, growth hormone, and TSH. In a large rando-
mized, controlled trial, De Backer and colleagues com-
pared dopamine with norepinephrine for the treatment of
patients with shock [35]. In the subgroup of patients with
septic shock, there was a trend toward improved outcome
with norepinephrine; however, this difference did not
reach statistical significance. A recent meta-analysis that
compared norepinephrine to dopamine in patients with
septic shock demonstrated a higher mortality with a signif-
icantly greater risk of arrhythmias with the use of dopa-
mine [24]. Therefore, this drug should be avoided in
patients with sepsis. Similarly phenylephrine is not recom-
mended, because in experimental models it decreases car-
diac output as well as renal and splanchnic blood flow
[36]. Furthermore, these agents have not been rigorously
tested in randomized, controlled studies.
EGDT and the Surviving Sepsis Campaign Guidelines
call for the administration of a blood transfusion in
patients’ with a central venous oxygen saturation (ScvO2)
of less than 70% and a hematocrit of less than 30% (Grade
2C recommendation) [3,5,6]. This recommendation is a
deviation from currently accepted transfusion practices,
and as stated by Barochia and colleagues, this recommen-
dation “may force physicians to provide unproven or even
harmful care” [8]. In the critically ill, blood transfusions
increase the risk of infections, acute respiratory distress
syndrome (ARD), multisystem organ failure (MSOF), and
death [37-39]. Although the intent of blood transfusions is
to increase tissue oxygenation, blood transfusions para-
doxically may have the opposite effect. Poorly deformable
transfused red blood cells may impede microvascular flow
[40]. Furthermore, the P50 of stored red cells may be as
low as 6 mmHg with the red blood cells being able to
unload less than 6% of the carried oxygen; stored cell may
thereby increase the ScvO2 (by binding oxygen) but com-
pound the tissue oxygen debt by decreasing oxygen
unloading.
Central venous oxygen saturation (ScvO2) was used as
the major endpoint of resuscitation in the intervention
arm of the River’ EGDT study (CVP > 8 cmH2Ow a s
targeted in both the control and intervention groups)
and is a Grade 2C recommendation in the Surviving
Sepsis Campaign Guidelines [5,6]. This is problematic
for a number of reasons [29]. Septic patients usually
have a normal or increased ScvO2 due to reduced oxy-
gen extraction [41,42]. A normal ScvO2 therefore does
not exclude tissue hypoxia. A low ScvO2 is an important
sign of inadequate oxygen delivery to meet systemic
oxygen demands. However, it provides no information
f o rt h er e a s o nf o rt h i si n a d e q u a c y ,n o rd o e si tp r o v i d e
guidance as to the optimal therapeutic approach. It is
noteworthy that in the Rivers study the mean ScvO2
was 49% with 65% of patients having a ScvO2 less than
70% [6].
No other sepsis study has reproduced this finding; the
mean ScvO2 (on presentation) in most sepsis studies is
approximately 70% [43-45]. This suggests that other fac-
tors may have been in play to account for the low ScvO2
in the Rivers study [15,46]. These factors include the
delayed presentation to hospital (possibly due to socioeco-
nomic factors), greater number of patients with comorbid
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[15]. Thus, the combination of significant comorbidities
(including heart disease) and a more delayed arrival of
patients to the emergency department in the River’s study
may have led to a low cardiac output state, and in turn, to
the very low ScvO2 values [44]. In a multicenter center
EGDT study that enrolled 619 patients, Pope et al.
reported that a high ScvO2 (ScvO2 > 90%) was an indepen-
dent predictor of death [47]. In this study, a low initial
ScvO2 (ScvO2 < 70%) was not predictive of mortality.
Figure 1 Suggested initial approach to the management of patients with severe sepsis and septic shock.
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by vasoactive agents (in those with persistent hypoten-
sion) remains the cornerstone of the management of
patients with severe sepsis and septic shock, the end-
points of resuscitation should be based on validated phy-
siologic variables that are individualized based on each
patients’ comorbidities and unique clinical circumstances
[13]. It is unlikely that a “one-size fits all” approach will
be appropriate for all patients. A number of multicenter,
randomized, controlled studies (ProCESS, ARISE) are
currently being undertaken, which are testing the effec-
tiveness of EGDT versus standard therapy [8]. These stu-
dies should aid in the development of an evidence-based
approach to the early resuscitation of patients with severe
sepsis and septic shock.
Conclusions
The past two decades have seen a remarkable growth in
our understanding of sepsis and the complex interconnec-
tion of multiple biological pathways involved in the septic
process. Despite initial enthusiasm with “disease-modify-
ing agents,” the early administration of appropriate anti-
biotics and early hemodynamic resuscitation remain the
cornerstone of the management of patients with sepsis.
This resuscitation of patients with sepsis should be based
on the best current scientific evidence and coordinated by
intensivists with expertise in managing these complex
patients. Unfortunately, despite good intentions the Sur-
viving Sepsis Campaign Guidelines are opinion-based
rather than evidence-based and should be abandoned.
Expert opinions are important but should be labeled as
such and not be incorporated into evidence-based clinical
practice guidelines.
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